Status:

RECRUITING

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors

Lead Sponsor:

Day One Biopharmaceuticals, Inc.

Collaborating Sponsors:

Pacific Pediatric Neuro-Oncology Consortium

Conditions:

Low-grade Glioma

Advanced Solid Tumor

Eligibility:

All Genders

6-25 years

Phase:

PHASE2

Brief Summary

This is a Phase 2, multi center, open-label study to evaluate the safety and efficacy of Type II RAF (tovorafenib) in pediatric participants with low-grade glioma or advanced solid tumors. Qualifying ...

Eligibility Criteria

Inclusion

  • Low Grade Glioma \& Low-Grade Glioma Extension: a relapsed or progressive LGG with documented known activating BRAF alteration.
  • Advanced Solid Tumor: locally advanced or metastatic solid tumor with documented known or expected to be activating RAF fusion.
  • Participants must have histopathologic verification of malignancy at either original diagnosis or relapse.
  • Must have received at least one line of prior systemic therapy and have documented evidence of radiographic progression.
  • Must have at least 1 measurable lesion as defined by RANO (Arms 1 \& 2) or RECIST v1.1 (Arm 3) criteria

Exclusion

  • Participant's tumor has additional previously-known activating molecular alterations.
  • Participant has symptoms of without radiographically recurrent or radiographically progressive disease.
  • Known or suspected diagnosis of neurofibromatosis type 1 (NF-1) via genetic testing or current diagnostic criteria.
  • Other inclusion/exclusion criteria as stipulated by protocol may apply

Key Trial Info

Start Date :

April 22 2021

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

May 31 2027

Estimated Enrollment :

141 Patients enrolled

Trial Details

Trial ID

NCT04775485

Start Date

April 22 2021

End Date

May 31 2027

Last Update

April 10 2025

Active Locations (35)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 9 (35 locations)

1

UCSF Benioff Children's Hospital

San Francisco, California, United States, 94143

2

Children's National Medical Center

Washington D.C., District of Columbia, United States, 20010

3

Lurie Children's Hospital of Chicago

Chicago, Illinois, United States, 60611

4

Johns Hopkins Hospital

Baltimore, Maryland, United States, 21231

A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors | DecenTrialz